Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02253030

OCT Angiography in Wet AMD

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to:

1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Neovascular (Wet) Age-related Macular Degeneration (AMD) Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

50 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Casey Eye Institute, Oregon Health & Science University

Portland, Oregon, 97239, United States

Location status: Recruiting

Location contact

Andreas Lauer, MD

SUB_INVESTIGATOR

Christina Flaxel, MD

SUB_INVESTIGATOR

Denny Romfh, OD

CONTACT

[email protected]

503-494-4351

George Pacheco, COA

CONTACT

[email protected]

503-494-7398

John Campbell, MD, PhD

SUB_INVESTIGATOR

Kavita Bhavsar, MD

SUB_INVESTIGATOR

Michael Klein, MD

SUB_INVESTIGATOR

Ou Tan, PhD

SUB_INVESTIGATOR

Phoebe Lin, MD, PhD

SUB_INVESTIGATOR

Thomas Hwang, MD

SUB_INVESTIGATOR

Yali Jia, PhD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Groups with wet AMD):

  • Adults aged 50 and older with clinical findings of treatment-naïve (never treated) neovascular AMD with active new blood vessel growth confirmed by clinical testing will be considered

Inclusion criteria

(Group with healthy eyes)

  • No evidence of retinal disease
  • Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx)
  • No recent eye surgery in the last 4 months
  • No significant cataract to interfere with the quality of the imaging

Exclusion criteria

(All Groups):

  • Inability to give informed consent
  • Significant kidney disease
  • Blood pressure greater than 180/110
  • Previous macular laser treatment
  • Inability to maintain stable fixation during OCT imaging
  • Visual acuity worse than 20/200

Treatment and study plan

optical coherence tomography

Device

Primary outcomes

  1. Measure of choroidal neovascular (CNV) vessel area in mm2

    Time frame: 1 year

  2. Measure of CNV membrane area in mm2

    Time frame: 1 year

  3. Measure of CNV length density in mm

    Time frame: 1 year

  4. Measure of retinal fluid volume in mm3

    Time frame: 1 year

  5. Measure of drusen area in mm2

    Time frame: 3 years

Study contacts

Contact information is provided by the study sponsor or research team.

Denny Romfh, OD

CONTACT

[email protected]

503-494-4351

George Pacheco, COA

CONTACT

[email protected]

503-494-7398

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Official study title

Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration

Important dates

Study start
2014
Primary completion
2026
Study completion
2026
First posted
Oct 1, 2014
Registry last updated
Feb 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.